title: Nutritional effects of the serial transverse enteroplasty procedure in experimental short bowel syndrome.
abstract: OBJECTIVE
  The serial transverse enteroplasty (STEP) procedure appears beneficial clinically, but the mechanism(s) underlying these effects remains unclear. The present study evaluated the nutritional, hormonal, and morphologic effects of the STEP procedure in a rodent model of short bowel syndrome.
  
  
  METHODS
  With institutional animal care ethics approval, Sprague-Dawley rats underwent an 80% distal bowel resection, anastomosing the 30 cm remnant of jejunum to the ascending colon; at day 14, animals were randomly assigned to control or a STEP procedure (n = 8/group). Animals were pair-fed with normal chow; after a further 3 weeks, intestinal transit, hormonal and metabolic balance studies were done, and intestinal tissues were taken for analysis.
  
  
  RESULTS
  The STEP group had increased weight gain (resected: -0.34% +/- 2.9% vs STEP: 2.5% +/- 1.5%), increased bowel length (34.1 +/- 1.5 vs 36.9 +/- 2.2 cm), increased jejunal villus height (555 +/- 59 vs 635 +/- 65 microm), decreased rates of crypt cell apoptosis, increased expression of mRNA for the GLP-2 receptor, and increased postprandial production of glucagon-like peptide 2 (45 +/- 14 vs 65 +/- 12 pmol/L) (P < .05 by Student t test). There were no differences in intestinal transit; absorption of total calories, protein, fat, or carbohydrate; crypt cell proliferation rates; or the expression of intestinal transporter proteins (SGLT-1, GLUT-2, and GLUT-5).
  
  
  CONCLUSIONS
  The STEP procedure improves weight gain and augments gross and microscopic intestinal morphology in severe experimental short bowel syndrome. Postprandial GLP-2 levels are increased, as is the expression of the GLP-2 receptor; these mechanisms may contribute to these metabolic effects and may be useful in guiding the use of the STEP procedure clinically.
authors.affiliation: Alberta Children's Hospital, Department of Surgery and Gastrointestinal Research Group, Institution of Infection Immunity and Inflammation, Faculty of Medicine, University of Calgary, Health Science Center, Calgary, Alberta, Canada.
authors.forename: Tatsuru
authors.initials: T
authors.lastname: Kaji
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Laurie E
authors.initials: LE
authors.lastname: Wallace
authors.forename: Dragan
authors.initials: D
authors.lastname: Kravarusic
authors.forename: Jens
authors.initials: J
authors.lastname: Holst
authors.forename: David L
authors.initials: DL
authors.lastname: Sigalet
mesh_terms: D000222:Adaptation, Physiological; D000714:Anastomosis, Surgical; D000818:Animals; D017209:Apoptosis / Q000502:physiology; D013505:Digestive System Surgical Procedures / Q000379:methods*; D004195:Disease Models, Animal; D053767:Glucagon-Like Peptide 2 / Q000378:metabolism; D000067758:Glucagon-Like Peptide-2 Receptor; D007408:Intestinal Absorption / Q000502:physiology; D019518:Postprandial Period; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018027:Receptors, Glucagon / Q000378:metabolism; D012778:Short Bowel Syndrome / Q000503:physiopathology / Q000601:surgery*; D015430:Weight Gain / Q000502:physiology*
chemical_list: D053767:Glucagon-Like Peptide 2; D000067758:Glucagon-Like Peptide-2 Receptor; D012333:RNA, Messenger; D018027:Receptors, Glucagon